icon-folder.gif   Conference Reports for NATAP  
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Barcelona, Spain
13-17 April 2016
Back grey_arrow_rt.gif
Sofosbuvir/Velpatasvir for 12 Weeks Is Well Tolerated and
Results in High SVR12 Rates in People Receiving Opioid Substitution Therapy

  Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
Jason Grebely,1 Gregory J. Dore,1 Richard Aspinall,2 Maribel Rodriguez-Torres,3 Raymond Fox,4 Lin Liu,5 Xiao Ding,5 John McNally,5 Anu Osinusi,5 Diana M. Brainard,5 G. Mani Subramanian,5 Mark Sulkowski,6 Jordan Feld7
1The Kirby Institute, Sydney, New South Wales, Australia; 2Portsmouth Hospitals NHS Trust, Portsmouth, UK; 3Fundación de Investigación, San Juan, Puerto Rico, USA; 4Brownlee Centre, Glasgow, UK;
5Gilead Sciences, Inc., Foster City, California, USA; 6Johns Hopkins University, Baltimore, Maryland, USA; 7Toronto Centre for Liver Disease, Toronto, Ontario, Canada